BIT Capital GmbH Acquires Shares of 15,000 Dianthus Therapeutics, Inc. $DNTH

BIT Capital GmbH acquired a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 15,000 shares of the company’s stock, valued at approximately $618,000.

Other large investors have also recently added to or reduced their stakes in the company. Patient Square Capital LP purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at $4,919,000. Vanguard Group Inc. grew its holdings in shares of Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after acquiring an additional 406,254 shares in the last quarter. UBS Group AG grew its holdings in shares of Dianthus Therapeutics by 342.6% during the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after acquiring an additional 469,547 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Dianthus Therapeutics during the 4th quarter valued at $765,000. Finally, Fairmount Funds Management LLC grew its holdings in shares of Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after acquiring an additional 600,000 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DNTH has been the topic of several research analyst reports. HC Wainwright boosted their price target on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Oppenheimer boosted their price target on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday, March 9th. Robert W. Baird upped their price objective on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday, March 10th. Finally, Truist Financial upped their price objective on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $117.82.

Dianthus Therapeutics Trading Down 4.3%

Shares of NASDAQ:DNTH opened at $80.51 on Friday. The stock has a market capitalization of $4.40 billion, a PE ratio of -19.49 and a beta of 1.18. Dianthus Therapeutics, Inc. has a 1 year low of $16.64 and a 1 year high of $96.50. The firm has a fifty day moving average price of $87.31 and a 200 day moving average price of $63.70.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at $362,480. The trade was a 86.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marino Garcia sold 122,918 shares of the business’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $10,016,587.82. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 349,551 shares of company stock valued at $28,968,156. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.